Showing results (111-120 of 140) with videos related to
Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
JIN-A02, a Mutant-Selective Fourth-Generation EGFR inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLCEun Ji Lee, Ji Ae Ko, Min-Je Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancerHye Ryun Kim, Dae Joon Kim, Dae Ryong Kang, et al.Communications Biology|April 10, 2021
Genomic landscape of extraordinary responses in metastatic breast cancerSun Min Lim, Eunyoung Kim, Kyung Hae Jung, et al.Therapeutic Advances in Medical Oncology|October 24, 2024
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancerSun Min Lim, Stefanie S Schalm, Eun Ji Lee, et al.Oral Oncology|November 23, 2025
Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 studyKevin J Harrington, Ari J Rosenberg, Muh-Hwa Yang, et al.Yonsei Medical Journal|December 16, 2021
Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin TumorChun-Bong Synn, Dong Kwon Kim, Jae Hwan Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2024
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel Neal, Nick Pavlakis, Sang-We Kim, et al.Nature Medicine|April 29, 2025
D3S-001 in advanced solid tumors with KRAS<sup>G12C</sup> mutations: a phase 1 trialByoung Chul Cho, Shun Lu, Myung Ah Lee, et al.Cancer Discovery|May 17, 2020
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion-Driven NSCLCJiyeon Yun, Soo-Hwan Lee, Seok-Young Kim, et al.Thoracic Cancer|October 7, 2020
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07Miso Kim, Bhumsuk Keam, Chan-Young Ock, et al.Pageof 14